Copolymer 1 from the laboratory to FDA.
Teitelbaum
D
D
Department of Immunology, Weizmann Institute of Science, Rehovot, Israel.
Sela
M
M
Arnon
R
R
D000276:Adjuvants, Immunologic / Q000737:chemistry* / Q000627:therapeutic use; D000818:Animals; D001327:Autoimmune Diseases / Q000188:drug therapy* / Q000276:immunology; D002986:Clinical Trials as Topic; D003429:Cross Reactions; D004195:Disease Models, Animal; D015195:Drug Design; D004681:Encephalomyelitis, Autoimmune, Experimental / Q000188:drug therapy / Q000276:immunology; D000068717:Glatiramer Acetate; D000949:Histocompatibility Antigens Class II / Q000276:immunology; D006801:Humans; D007166:Immunosuppressive Agents / Q000737:chemistry* / Q000276:immunology / Q000627:therapeutic use; D007557:Israel; D007753:Laboratories; D009103:Multiple Sclerosis / Q000188:drug therapy* / Q000276:immunology; D010455:Peptides / Q000737:chemistry* / Q000276:immunology / Q000627:therapeutic use; D011108:Polymers / Q000737:chemistry* / Q000627:therapeutic use; D013601:T-Lymphocytes / Q000187:drug effects / Q000276:immunology; D050378:T-Lymphocytes, Regulatory / Q000187:drug effects / Q000276:immunology; D014481:United States; D014486:United States Food and Drug Administration
D000276:Adjuvants, Immunologic; D000949:Histocompatibility Antigens Class II; D007166:Immunosuppressive Agents; D010455:Peptides; D011108:Polymers; D000068717:Glatiramer Acetate